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Relapse occurs in 30%-50% of recipients of T celledepleted (TCD) reduced-intensity conditioned (RIC)
hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) and myelodysplastic
syndromes (MDS). Despite limited published supportive data, donor lymphocyte infusion (DLI) is used
preemptively (pDLI) to improve donor chimerism and prevent relapse, and therapeutically (tDLI) after disease
recurrence. We evaluated the efﬁcacy and toxicity of pDLI and tDLI in 113 patients after TCD (alemtuzumab,
n ¼ 99; antithymocyte globulin, n ¼ 14) RIC HSCT for AML or MDS. Recipients of pDLI (n ¼ 62) had an
estimated 5-year overall survival (OS) of 80% and an event-free survival of 65%. More than one-half (52%;
n ¼ 32) of the patients received pDLI within 6 months post-HSCT; despite this, the 5-year incidence of graft-
versus-host disease was only 31% (95% conﬁdence interval [CI], 19%-43%). Recipients of tDLI (n ¼ 51) had an
estimated 5-year OS of 40% and a 5-year relapse/progression rate of 69% (95% CI, 54%-81%). Recipients of tDLI
at >6 months post-HSCT had a signiﬁcantly superior 5-year OS after tDLI compared with those treated earlier
(P ¼ .008). The cumulative incidence of graft-versus-host disease at 5 years after tDLI was 45% (95% CI,
23%-65%). We demonstrate that pDLI safely promotes durable remission after TCD RIC HSCT for AML or MDS,
and that tDLI salvages patients after late relapse with greater efﬁcacy.
 2013 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION rates of GVHD [13]. This is relevant particularly for patients
Allogeneic hematopoietic stem cell transplantation
(HSCT) remains the sole curative therapy for patients with
intermediate-risk or poor-risk acute myelogenous leukemia
(AML) andmyelodysplastic syndromes (MDS) [1,2]. Reduced-
intensity conditioning (RIC) regimens allow the use of HSCT
in older patients and in those with comorbidities by carrying
lower nonrelapse mortality (NRM) [3-5]. NRM andmorbidity
are further improved by T cell depletion (TCD), using alem-
tuzumab or antithymocyte globulin (ATG), which reduces
severe graft-versus-host disease (GVHD) [6,7].
Relapse is the major cause of treatment failure after TCD
RIC HSCT [8,9]. Delayed immune reconstitution after RIC
with an alemtuzumab-containing regimen might contribute
to the relapse risk through a reduced graft-versus-leukemia
(GVL) effect [10-12]. To counter this, donor lymphocyte
infusion (DLI) is commonly administered after TCD RIC HSCT,
which enhances the GVL effect [13,14]. Low or declining
donor T cell chimerism may herald impending relapse [15]
and guide preemptive DLI (pDLI) to improve chimerism
and maintain remission. There is currently no consensus
regarding the timing and dosing of pDLI after TCD RIC HSCT
for AML/MDS [16,17]. Indeed, an earlier study suggested that
pDLI given before 6 months after TCD RIC HSCT induced highedgments on page 567.
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12.12.013with AML/MDS, who are at greatest risk for relapse at 6-12
months after TCD RIC HSCT [7]. Whether administration of
pDLI before 6 months after TCD RIC HSCT is safe and efﬁca-
cious remains undetermined. After disease recurrence
post-HSCT, tDLI may be used alone or in combination
with chemotherapy as salvage therapy. Although some
studies support tDLI to treat relapse of AML/MDS after
T cellereplete or myeloablative HSCT [18-20], data after TCD
RIC HSCT is limited [16,17]. Thus, we sought to review
outcomes after preemptive and therapeutic DLI administra-
tion in patients treated with TCD RIC HSCT for AML and MDS
at our institution between 1999 and 2010.
METHODS
Patients
A total of 113 patients treated with DLI after TCD RIC HSCT for AML, MDS,
and MDS/myeloproliferative neoplasm (MPN), deﬁned according to the
World Health Organization classiﬁcation scheme [21], were identiﬁed.
Cytogenetic risk was determined when applicable [22,23]. Pre-
transplantation patient characteristics are presented in Table 1. All patients
received a ﬂudarabine and busulfan-based RIC regimen (details of regimens
are provided in Table S1). The total ﬂudarabine dose was 150 mg/m2, and
total busulfan dose was 6.4mg/kg i.v. (n¼ 67), 12.8 mg/kg i.v. (n¼ 13), 8 mg/
kg orally (n¼ 27), or 16mg/kg orally (n¼ 6). In vivoTcell depletion in sibling
and unrelated donor transplantations was done using 20 mg alemtuzumab
(Campath; Genzyme, Boston, Massachusetts) daily from day -8 to day -4.
From 2007, 6 mg/kg (total dose) antithymocyte globulin (ATG; Genzyme) on
day -4 to day -1 was used in sibling donor HSCT. For GVHD prophylaxis,
cyclosporine (1.5 mg/kg i.v. twice daily, orally after recovery of oral intake)
was started on day -1, titrated according to plasma trough levels (range,150-
200 ng/L), and tapered from day þ56 onward.
erican Society for Blood and Marrow Transplantation.
Table 1
Characteristics of the pDLI and tDLI Cohorts
Characteristic pDLI (n ¼ 62) tDLI (n ¼ 51) P Value
Age, years, median (range) 54 (19-69) 55 (29-72) .09
Sex, male/female, n 29/33 32/19 .09
Conditioning, n
Fludarabine/busulfan/Campath 56 43 .26
Fludarabine/busulfan/ATG 6 6
FLAMSA 0 2
Donor, n
Sibling 28 23 .57
Matched unrelated 34 28
Stem cell source, n
Bone marrow 14 9 .27
Peripheral blood stem cells 48 42
HLA matching, n
10/10 match 49 43 .57
8-9/10 match 13 8
Diagnosis, n
AML (de novo, secondary) 34 (17, 17) 24 (11, 13) .28
MDS RAEB I/II 13 15
MDS RCMD 12 6
MDS/MPN 3 6
Cytogenetic risk group, n*
Good 15 (1/14) 9 (1/8) .75
Intermediate 29 (22/7) 24 (16/8)
Poor 8 (4/4) 8 (3/5)
Not available 10 11
Disease status at transplantation, n (%)
<5% blasts 52 (84) 41 (80) .31
>5% blasts 2 (3) 5 (10)
Cytogenetic disease 4 (6) 2 (4)
Missing data 4 (6) 3 (6)
GVHD post-HSCT, n
None 54 37 .044
Acute GVHD grade I-II 7 6
Acute GVHD grade III-IV 0 2
Chronic GVHD 1 6
Time to DLI, days, median (range) 176 (87-1304) 277 (74-2801) <.01
Donor CD3% pre-DLI, median (range) 23 (0-77) 87 (0-100) <.01
Number of DLI doses, median (range) 2 (1-7) 2 (1-8) .21
Total DLI dose, CD3þ cells/kg, median (range) 1.5  106 (1  105-1.66  108) 9.5  106 (5  105-1.43  108) .03
FLAMSA indicates ﬂudarabine/amsacrine/cytarabine; RAEB, refractory anemia with excess of blasts; RCMD, refractory cytopenia with multilineage dysplasia.
* Total number followed by breakdown of numbers in AML/MDS groups. Cytogenetic groups were deﬁned using the International Prognostic Scoring System
[22] for MDS and revised Medical Research Council classiﬁcation for AML [23].
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Chimerism was assessed routinely at days þ28, þ56, þ100, þ180,
and þ365 post-HSCT and at 3- to 6-month intervals thereafter. PCR and
ﬂuorescent analysis of short tandem repeat sequences on bone marrow or
whole blood and peripheral blood CD3þ and CD15þ cell fractions using the
Promega PowerPlex 16 System (Promega, Madison, WI), along with X,Y-
ﬂuorescence in situ hybridization in donorerecipient sex mismatches,
were used for chimerism assessment. Full donor chimerism (FDC) was
deﬁned as donor CD3 percentage (CD3%) 95%; mixed donor chimerism
(MDC), as donor CD3% of 5%-94%. Relapse was deﬁned as detection of >5%
myeloblasts by morphology and/or detection of new/recurrent cytogenetic
changes using metaphase and X,Y-ﬂuorescence in situ hybridization
analyses.
DLI Administration and Monitoring; Assessment of GVHD
Institutional protocol required that all patients with progressively
declining donor CD3 chimerism or relapsed disease post-TCD RIC HSCT
receive pDLI or tDLI, respectively. DLI was administered using an escalating
dose schedule (Table S2) to patients off immunosuppression and without
GVHD. The same dosing schedule was used irrespective of donor type
(sibling versus matched unrelated) or degree of HLA-mismatch.
pDLI was administered after dayþ100 to patients with persistent donor
CD3% <50% or declining CD3% (a drop of at least 20% on successive
assessments 4-6 weeks apart). Mixed chimeric patients who were on
cyclosporine therapy had pDLI withdrawn before conﬁrming the require-
ment for pDLI by repeat chimerism assessment. The chimerism response to
pDLI was determined by the achievement of either sustained FDC or stable
MDC (CD3% <95%).
tDLI was administered to patients either alone or after chemotherapy for
relapse. In addition to chimerism analysis, bone marrow assessments
(morphology, cytogenetics, and immunophenotyping) were performed toevaluate response to tDLI. GVHD (acute [aGVHD] and chronic [cGVHD]) was
assessed according to published criteria [24,25], with histological conﬁr-
mation whenever possible.
Statistical Analyses
Patients were censored at July 1, 2011, or at the date of last known
follow-up, death, or second HSCT. Patient, disease, and transplantation-
associated variables were compared using the c2 test or Fisher exact test
for categorical variables and the Mann-Whitney U test for continuous
variables. Overall survival (OS) after DLI was deﬁned as the interval from
ﬁrst DLI administration to the date of censoring. Event-free survival (EFS)
post-DLI was deﬁned as the interval from ﬁrst DLI until the date of censoring
or relapse. Survival curves were estimated according to the Kaplan-Meier
method. Two-tailed P values <.05 were considered signiﬁcant. Analysis of
cGVHD post-pDLI with respect to chimerism was performed using univar-
iate logistic regression, with chimerism categorized as FDC, MDC, or no
sustained improvement in chimerism and treated as ordered categories.
Incidence of GVHD was analyzed by competing-risk analysis using the
method of Fine and Gray [26], with relapse considered a competing risk with
cGVHD. All statistical analyses were performed using Stata version 11.2
(StataCorp, College Station, TX).
RESULTS
A total of 113 patients with AML (n ¼ 58; 50%), MDS
(n ¼ 46; 40%), or MDS/MPN (n ¼ 9; 10%) received pDLI
(n ¼ 62; 55%) or tDLI (n ¼ 51; 45%). Median age at HSCT was
53 years (range, 19-72 years). Fifty-two pDLI recipients (84%)
and 41 tDLI recipients (80%) were in morphological remis-
sion at HSCT. Donors were fully matched siblings in 51 cases
Table 2
DLI
DLI Characteristic pDLI Cohort tDLI Cohort
Infusion 1, n 62 51
Achievement of FDC, n (%) 11 (18)
Time post-HSCT to DLI 1, days, median (range) 180 (87-1304) 277 (74-2801)
CD3þ cell dose, cells/kg, median (range) 5  105 (1  105-5  106) 1  106 (5  105-1  107)
Time between infusions 1 and 2, days, median (range) 60 (20-149) 49 (16-189)
Infusion 2, n 39 34
Achievement of FDC, n (%) 13 (21)
Time post-HSCT to DLI 2, days, median (range) 232 (139-482) 381 (90-1391)
CD3þ cell dose, cells/kg, median (range) 1  106 (5  105-1  107) 5  106 (1  106-3.2  107)
Time between infusions 2 and 3, days, median (range) 46 (25-283) 53 (14-77)
Infusion 3, n 17 8
Achievement of FDC, n (%) 7 (11)
Time post-HSCT to DLI 3, days, median (range) 363 (262-764) 597 (234-1468)
CD3þ cell dose, cells/kg, median (range) 5  106 (4.5  106-1  107) 7.5  106 (5  106-5  107)
Time between infusions 3 and 4, days, median (range) 50 (30-125) 51 (34-152)
Infusions 4-8, n* 8 4
Achievement of FDC, n (%) 4 (6)
Time post-HSCT to DLI 4, days, median (range) 404 (326-494) 403 (371-1535)
Total CD3þ cell dose (doses 4-8), cells/kg, median (range)y 6.4  107 (1.65  107-1.66  108) 7.85  107 (1.65  107-1.43  108)
* The number (and percentage) of patients in the pDLI cohort who achieved FDC after 1, 2, 3, or 4-8 infusions (total, n ¼ 35; 56%).
y Maximum number of doses given was 7 in the pDLI cohort and 8 in the tDLI cohort.
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whom 41 [66%] were fully HLA matched at HLA-A, -B, -C,
-DRB1, and -DQ; 21 [34%] were 1 or 2 antigen mismatched)
There were no signiﬁcant differences between the 2 cohorts
with respect to disease or transplant characteristics (Table 1).
pDLI Administration and Chimerism Responses
Sixty-one patients received the ﬁrst dose of pDLI at
a median of 176 days (range, 87-461 days); a single patient
received pDLI for a late development of MDC at 1304 days
(Table 2). Median times fromHSCT to subsequent doses were
232 days (range, 139-482 days) for dose 2, 363 days (range,
262-764 days) for dose 3, and 404 days (range, 326-494 days)
for dose 4 (Table 2). Four patients received a ﬁfth dose of pDLI
at a median of 538 days (range, 367-776 days) post-HSCT,
and 1 patient received a total of 7 doses.
pDLI was started at 5  105 CD3þ cells/kg in 46 patients
(74%); a lower starting dose of 1  105 CD3þ cells/kg was
given in 3 patients with recent grade II GVHD. The starting
dose was 1  106 CD3þ cells/kg (n ¼ 10) or 5  106 CD3þ
cells/kg (n¼ 3), owing to very low chimerism (0% donor CD3)
or poor risk features for HSCT (eg, persistent disease, adverse
cytogenetics). Cyclosporine had been stopped by a median of
78 days post-HSCT (range, 39-229 days; treatment extended
beyond 100 days in 1 patient with suspected, but subse-
quently unconﬁrmed, liver GVHD). All patients were off
immunosuppression at the time of pDLI initiation; the
median interval from cessation of cyclosporine to the ﬁrst
dose of pDLI was 70 days (range, 25-193 days).
Themedian donor CD3% in pDLI recipients before infusion
was 23% (range, 0-77%). Median donor CD15 and unfractio-
nated peripheral blood chimerism were 100% (range,
43%-100%) and 89% (range, 24%-100%), respectively. Chime-
rism response was evaluable in 56 patients; chimerism
datasets were incomplete in 6 patients. Forty-two of these
patients (67%) achieved sustained FDC (n¼ 35; 56%) or stable
MDC (n ¼ 7; 11%). Mean CD3% achieved was 76% (95%
conﬁdence interval [CI], 69%-83%) in the patients attaining
stable MDC. Sixteen of these 42 responders (38%) received
a single dose of pDLI; 14 (33%) received 2 doses (median total
dose, 1.5  106 CD3þ cells/kg; range, 1.1 106-1.5  107 CD3þ
cells/kg). Eight of them (19%) received 3 doses (median totaldose, 6.5106 CD3þ cells/kg; range, 6.0 106-1.6 107 CD3þ
cells/kg) and 4 (10%) were given 4-7 doses (median total
dose, 6.15  107 CD3þ cells/kg; range, 1.65  107-1.64  108
CD3þ cells/kg).
Fourteen of these 56 patients relapsed, at a median of 128
days (range, 13-394 days) after ﬁrst pDLI. Eight of these
patients showed no change in CD3%, whereas the other 6 had
a maximum increase in donor CD3% of 20%-30%. The starting
dose was 5  105 CD3þ cells/kg in 11 of these patients; 3
patients had a higher starting dose (2 with 1  106 CD3þ
cells/kg and 1 with 5  106 CD3þ cells/kg). Relapse occurred
after 1-2 doses (n ¼ 10; median total dose, 1.25  106, range,
5  105-1.5  107 CD3þ cells/kg) or 3-5 doses (n ¼ 4; median
total dose, 6.4  107, range 1.15  107-1.66  108 CD3þ
cells/kg). Four of the 14 patients died, 5 underwent a second
HSCT (median disease-free survival after second HSCT, 949
days; range, 136-2359 days), and 4 had stable disease at
censor date (median OS post-pDLI, 987 days; range, 415-
1542 days). The remaining patient received reinduction
chemotherapy, consolidated with further DLI.
Absolute donor CD3% before pDLI was not signiﬁcantly
different between this group of 14 patients and those who
attained sustained FDC or stable MDC (P ¼ .73). In addition,
there were no signiﬁcant differences in the unfractionated
peripheral blood (P ¼ .80) or CD15 (P ¼ .80) donor
percentages between these 2 groups. No differences were
found with respect to disease, transplantation (condi-
tioning or donor type), or DLI variables (cumulative or
starting dose and number of doses) (data not shown). Six
patients had a total absence of detectable donor CD3þ cell
lineage; 3 of these patients showed no response to pDLI
and relapsed, whereas the other 3 patients achieved FDC.
Patients who attained sustained FDC or stable MDC post-
pDLI had a signiﬁcantly superior 5-year OS after pDLI of
91%, compared with 62% in the 14 patients who demon-
strated no sustained improvement in chimerism after pDLI
(P < .01).
Preemptive DLI for Low or Falling Chimerism Maintains
High Remission Rates
The median follow-up after ﬁrst pDLI was 1428 days
(range, 75-3625 days). Five-year OS and EFS in 62 recipients
Figure 1. (A) Estimated OS for the pDLI cohort. OS calculated by the method of
Kaplan-Meier demonstrated 80% 5-year survival after ﬁrst pDLI. (B) Estimated
EFS for the pDLI cohort. EFS calculated by the method of Kaplan-Meier
demonstrated 65% 5-year survival after ﬁrst pDLI.
Table 3
DLI-Related Toxicity and Causes of Death
Outcome pDLI, n tDLI, n
Death due to
Relapse 7 23*
GVHD 2 1
Sepsis 1 2
Multiorgan failure, cause unknown 0 1
GVHD post-DLI
Acute GVHD (total) 4 3
Grade II skin 1 2
Grade III-IV skin/gut/liver 3 1
Limited chronic GVHD (total) 3 1
Liver 2 0
Skin/oral 1 1
Extensive chronic GVHD (total) 12 17
Skin/liver/gut 10 12
Sclerodermatous chronic GVHD 2 5
GVHD therapy
Topical only 2 2
Up to 2 systemic agents 7 10
Three systemic agents 4 8
Refractory GVHD requiring anti-TNF antibody 2 0
Data unavailable 4 1
Other complications of GVHD or its therapy
Infection (including cytomegalovirus reactivation) 2 1
Steroid side effects (diabetes, avascular necrosis) 1 3
Surgical intervention for complications of gut
GVHDy
1 0
* Includes deaths resulting from failure to respond to tDLI or subsequent
relapse after response to tDLI.
y One cacostomy owing to perforated viscus.
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factor, disease variable (eg, primary diagnosis, cytogenetic
risk group), or transplantation characteristic had a signiﬁcant
impact on OS or EFS (data not shown). Only 3 patients who
achieved sustained FDC (n ¼ 2) or stable MDC (n ¼ 1)
experienced subsequent disease relapse, at a median of 1240
days after ﬁrst pDLI (range, 335-2257 days). Two of these 3
patients were salvaged with further DLI after remission
reinduction. In total, 10 of 62 patients died, owing to disease
relapse (n ¼ 7), GVHD (n ¼ 2), or sepsis (n ¼ 1).
Thirty-two patients (52%) received pDLI within 6 months
post-HSCT; the incidence of GVHDwas onlymoderate, at 31%
(n ¼ 19) (Table 3). The median time to GVHD after ﬁrst pDLI
was 68 days (range, 34-398 days); a patient who received
a total of 7 doses developed GVHD at 398 days after the ﬁrst
dose of pDLI. Four patients (6%) developed grade II-IV
aGVHD, 3 (5%) developed limited GVHD, and 12 (19%)
developed extensive cGVHD. Thirteen of the 19 patients
(68%) who developed GVHD attained FDC, and 1 patient (5%)
achieved stable MDC; logistic regression analysis showed
that a chimerism response to pDLI was signiﬁcantly associ-
ated with the development of GVHD (P ¼ .026). No other
variables, such as disease or transplantation characteristics
(including donor type and stem cell source) or cumulativepDLI dose, were associated with the development of GVHD
post-pDLI (data not shown).
Salvage Therapy Incorporating tDLI May Rescue
a Proportion of Patients with Recurrent Disease
Post-HSCT
Median time to relapse was 272.5 days (range, 62-2654
days). Median follow-up after ﬁrst tDLI was 274 days (range,
23-3337 days). Estimated 5-year OS after tDLI was 40%
(median, 705 days; 95% CI, 102-1308 days). Patients who
relapsed before 6 months post-HSCT had a signiﬁcantly
inferior 5-year OS after tDLI (11% versus 51% for those who
relapsed beyond 6 months; P ¼ .008) (Figure 2) and a greater
frequency of donor CD3% of <50% at relapse (60% versus 6%
in those with later relapse; P < .001). Estimated 5-year OS
after tDLI was 65% for patients with good-risk cytogenetics,
33% for those with intermediate-risk cytogenetics, and 0% for
those with poor-risk cytogenetics (P < .01, good versus poor
and intermediate versus poor) (Figure 3).
Cytogenetic data at relapse were available in 39 patients
and included normal karyotype in 21, recurrence of original
cytogenetic abnormality in 12, and new clonal changes (part
of a complex karyotype in all) in 6. However, relapse
karyotype had no impact on post-tDLI OS (P ¼ .39). The
presence of >5% blasts in the bone marrow before tDLI was
also signiﬁcantly associated with an inferior 5-year OS (24%
versus 53% for patients in morphological complete remis-
sion (CR) before tDLI; P < .01).
Immunosuppression had been tapered and stopped by
a median of 77 days (range, 40-485 days) after HSCT in this
cohort. Nine patients (18%) were receiving immunosup-
pressive therapy at the time of relapse. Three patients
relapsed while on immunosuppressive therapy to treat
GVHD (beyond 100 days post-HSCT). Six other cases had
relapsed while on immunosuppression in the early
Figure 2. Estimated OS for the tDLI cohort, stratiﬁed by time to ﬁrst DLI post-
HSCT. Patients requiring tDLI at >6 months post-HSCT had a signiﬁcantly
superior OS after ﬁrst tDLI compared with patients requiring therapy before 6
months.
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ables affected OS post-tDLI (data not shown).
Thirty-ﬁve of the 51 patients who received tDLI also
received chemotherapy (28 intensive, 7 low-dose; Table S3).
Twenty-three patients achieved morphological CR post-
chemotherapy. Eighteen remained in remission after tDLI;
however, 8 patients relapsed later, and another 2 died (1 of
GVHD and 1 of multiorgan failure). Eight patients were alive
and disease-free at the time of censoring, with a median
post-tDLI OS of 1711 days (292-2749 days).
Five patients who achieved CR post-chemotherapy
relapsed during tDLI treatment. Another 12 patients
showed no improvement in disease burden after chemo-
therapy and tDLI. Of these 17 patients, 4 were alive and
receiving further chemotherapy at the time of censoring.
Sixteen patients received tDLI alone. All 4 patients who
responded had cytogenetic relapse only. One patient died of
sepsis after attainment of CR; 3 were alive at the time of
censoring, with a median post-tDLI OS of 976 days (range,
464-3337 days). No difference in post-tDLI OS was seen
between those patients who received both chemotherapy
and tDLI and those who received tDLI alone (P ¼ .1).Figure 3. Estimated OS for the tDLI cohort, stratiﬁed by cytogenetic risk group
at diagnosis [22,23]. OS at 5 years post-tDLI was estimated at 65% for good-risk
patients, 33% for intermediate-risk patients, and 0% for poor-risk patients.The starting dose of tDLI was 5  105 CD3þ cells/kg in 18
patients (35%), 1  106 CD3þ cells/kg in 13 patients (26%),
5  106 CD3þ cells/kg in 9 patients (18%), and 1  107 CD3þ
cells/kg in 11 patients (22%), with subsequent dose escalation
(Table 2). Twenty-two patients in remission after tDLI (18
after chemotherapy and tDLI and 4 after tDLI alone) received
a median of 2 doses (range, 1-8), with a median total dose of
8.25  106 CD3þ cells/kg (range, 5  105-1.43  108 CD3þ
cells/kg). Twenty-nine nonresponders (no response or
disease progression during tDLI) received a median of 2
doses (range 1-4); median total dose was 9.5  106 CD3þ
cells/kg (range, 5  105-6  107 CD3þ cells/kg). There was no
signiﬁcant difference in the cumulative dose of tDLI between
responders and nonresponders (data not shown).
GVHD occurred in 21 patients (41%) after tDLI, including
3 (6%) with aGVHD and 18 (35%) with cGVHD, which was
extensive in 17 (33%) (Table 3). Median time to the devel-
opment of GVHD after ﬁrst tDLI was 84 days (range, 19-323
days). GVHD occurred more frequently in those who
experienced remission after tDLI, affecting 60% of
responders versus 29% of nonresponders (P ¼ .03), but had
no impact on post-tDLI OS (data not shown). There was no
signiﬁcant difference in the mean cumulative dose of tDLI
between patients who developed extensive cGVHD and
those who developed only limited or no cGVHD (P ¼ .90).
Grade IV gut aGVHD accounted for 1 death. Relapse/
refractory disease accounted for the majority of the deaths
(86%; 23 of 27) in the tDLI cohort.
DISCUSSION
The advent of RIC has made HSCT feasible in older
patients with AML and MDS [3-5], as illustrated by our
cohort’s median age of 54 years. TCD aims to facilitate
engraftment in RIC HSCT and to reduce the incidence of
GVHD in high-risk older patients [11,27]. However, RIC
[4,5,28] and TCD [8,9] have been implicated in the persistent
risk of relapse post-HSCT, through a reduced GVL effect. TCD
is frequently associated with prolonged mixed donor
chimerism, most clearly described after alemtuzumab
administration [29,30]. An increased risk of relapse has been
reported in patients with MDC or progressively decreasing
donor chimerism [15,31], suggesting a role for pDLI in
improving chimerism and boosting the GVL effect. This was
recently demonstrated after TCD RIC HSCT for lymphoma,
where pDLI effectively converted MDC to FDC and reduced
the risk of relapse [32,33].
The aim of the present analysis was to review outcomes
after pDLI and tDLI in a single-center cohort of patients with
AML and MDS after a RIC protocol including in vivo T cell
depletionwith alemtuzumab or ATG. We have demonstrated
that pDLI given to revert low or falling donor CD3 chimerism
after TCD RIC HSCT (predominantly incorporating alemtu-
zumab) can effectively prevent relapse. Only 3 patients with
sustained FDC or stable MDC after pDLI subsequently
relapsed (at a minimum of 335 days after pDLI). This suggests
that pDLI provides effective GVL activity against AML/MDS
even in patients at high risk for disease recurrence. In
contrast, relapse was observed in all patients who did not
show a sustained improvement in donor chimerism after
pDLI.
More than one-half of our cohort of older patients
received pDLI before 6 months post-HSCT. Despite early
treatment with pDLI, rates of GVHD were only moderate in
the pDLI cohort; 19 patients developed GVHD, 12 with
extensive cGVHD. Only 2 deaths were attributed to GVHD.
P. Krishnamurthy et al. / Biol Blood Marrow Transplant 19 (2013) 562e568 567Furthermore, infectious complications (including cytomeg-
alovirus reactivation) related to GVHD or its therapy were
infrequent (2 patients; Table 3). Our results contrast with
a 2002 registry study of DLI administration after TCD RIC
HSCT, suggesting high rates of GVHD (>50%) after treatment
before 6 months [13]. In this study of 81 patients with
lymphoid and myeloid malignancies receiving DLI, 18 were
treated for MDC. Most patients had undergone HSCT with
persistent disease, not all had received alemtuzumab, and
the dosage varied among regimens (100 mg versus 50 mg)
[13]. Although there has been a report of DLI administration
in some cases even before 100 days after myeloablative and
RIC HSCT [34], the present study is the ﬁrst to report results
of early, escalating-dose pDLI in a uniform cohort of TCD RIC
HSCT recipients with AML and MDS.
In the setting of tDLI, superior 5-year OS was seen in
patients requiring tDLI for relapse more than 6 months after
TCD RIC HSCT and those with a pre-tDLI bone marrow blast
percentage <5%. Interestingly, karyotype at diagnosis also
inﬂuenced 5-year OS. The majority of patients in our cohort
had received chemotherapy in combination with tDLI,
making it difﬁcult to separate out the contributions of each
modality to our results. When tDLI was given alone, it was
efﬁcacious only in those with low tumor burden (cytogenetic
relapse only). Our ﬁndings conﬁrm previous results of tDLI
after myeloablative HSCT from Schmid et al. [20], who re-
ported improved OS at 2 years for patients who relapsed
beyond 5 months or in morphological remission before tDLI.
Delayed immune reconstitution has been reported after
TCD HSCT, particularly when alemtuzumab is used. This delay
is associated with infection, viral reactivation [11,35], and
a negative impact onGVL activity [8,9]. Indeed, the statistically
signiﬁcant association of GVHD with chimerism response to
pDLI and attainment of remission in our tDLI cohort supports
the provision of an active alloimmune response by DLI in
responding patients. An earlier study from our center found
a trend toward fewer relapses of AML/MDS after pDLI in
patients withMDC compared with patients with spontaneous
FDC or stable MDC who had not received DLI [17]. The bene-
ﬁcial effects speciﬁcally of pDLI may reﬂect correction of
deﬁciencies in the immune cell repertoire after TCD HSCT. We
havepreviously demonstrated that although early lymphocyte
recoverywas robust inpatients afterﬂudarabine, busulfan and
alemtuzum HSCT for AML/MDS who subsequently relapsed
[12], there were marked deﬁciencies in the frequency of CD4þ
T cells and naïve T cells in both the CD4þ and CD8þ cell pop-
ulations for at least 6 months after HSCT [36].
After HLA-matched HSCT, T cells capable of recognizing
minor histocompatibility antigen (mHag) disparities may
contribute to GVL activity; by deﬁnition, such donor-derived
T cells will be naïve [37,38]. mHag-speciﬁc T cell clones
capable of lytic activity against leukemia cells have been
isolated from patients after DLI [39,40]. Thus, a possible
mechanism for the GVL activity of DLI may be the provision
of naïve donor-derived T cells, which increases the T cell
repertoire capable of tumor cytotoxicity; this remains an
exciting area of future research.
In conclusion, our data support the utility of TCD RIC HSCT
as an immune platform for treating AML and MDS, in which
the judicious early use of pDLI can safely promote durable
remission. Therapeutic DLI may be combined with chemo-
therapy to salvage a proportion of patients with recurrent
disease, particularly those who relapse beyond 6 months
post-HSCT. Prospective studies are needed to more clearly
address the efﬁcacy of this intervention by comparingoutcomes in patients after DLI and patients not exposed to
this therapy.
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